비소세포폐암 환자의 표적 치료
Targeted Therapy of Advanced Non-Small Cell Lung Cancer
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Lung cancer is the leading cause of cancer death in Republic of Korea. After their initial diagnosis, only 10-20% of patients with advanced non-small cell lung cancer (NSCLC) survive for 5 years of longer. Given enormous advances in therapeutics such as novel targeted therapies and immunotherapies, survival rates are improving for advanced patients with NSCLC; 5-year survival rates range from 15% to 50%, contingent upon the biomarker. Detection of the specific molecular alteration as biomarker is thus crucial for identifying subgroups of NSCLC that contain therpapeutically targetable oncogenic drivers. This review examines the process of diagnosing lung adenocarcinoma with dominant biomarkers in order to customize treatment with appropriate targeted therapy.
Abstract
Lung cancer is the leading cause of cancer death in Republic of Korea. After their initial diagnosis, only 10-20% of patients with advanced non-small cell lung cancer (NSCLC) survive for 5 years of longer. Given enormous advances in therapeutics such as novel targeted therapies and immunotherapies, survival rates are improving for advanced patients with NSCLC; 5-year survival rates range from 15% to 50%, contingent upon the biomarker. Detection of the specific molecular alteration as biomarker is thus crucial for identifying subgroups of NSCLC that contain therpapeutically targetable oncogenic drivers. This review examines the process of diagnosing lung adenocarcinoma with dominant biomarkers in order to customize treatment with appropriate targeted therapy.
참고문헌 (21)
- Nicholson AG, "The 2021 WHO classification of lung tumors : impact of advances since 2015", J Thorac Oncol, 17, pp.362~387 (2022)
- Travis WD, "International Association for the Study of Lung Cancer", American Thoracic Society, J Thorac Oncol, pp.2011, 6[DOI]
- Hendriks LE, "Oncogene-addicted metastatic non-small-cell lung cancer : ESMO clinical practice guideline for diagnosis, treatment and follow-up", Ann Oncol, 34, pp.339~357 (2023)
- Ettinger DS, "Non-small cell lung cancer, version 3. 2022, NCCN clinical practice guidelines in oncology", J Natl Compr Canc Netw, 20, pp.497~530 (2022)
- Amin MB, "The eighth edition AJCC cancer staging manual : continuing to build a bridge from a population-based to a more"personalized"approach to cancer staging", CA Cancer J Clin, 67, pp.93~99 (2017)
- Passaro A, "ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer", Ann Oncol, 33, pp.466~487 (2022)
- Cho BC, "Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small-cell lung cancer : results from LASER301", J Clin Oncol, 41, pp.4208~4217 (2023)
- Soria JC, "Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer", N Engl J Med, 378, pp.113~125 (2018)
- Ramalingam SS, "Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC", N Engl J Med, 382, pp.41~50 (2020)
- Park K, "Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy : initial results from the CHRYSALIS phase I study", J Clin Oncol, 39, pp.3391~3402 (2021)
- Yang JC, "Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations : a database of 693 cases", J Thorac Oncol, 15, pp.803~815 (2020)
- Selinger CI, "Testing for ALK rearrangement in lung adenocarcinoma : a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization", Mod Pathol, 26, pp.1545~1553 (2013)
- Solomon BJ, "First-line crizotinib versus chemotherapy in ALK-positive lung cancer", N Engl J Med, 371, pp.2167~2177 (2014)
- Peters S, "Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer", N Engl J Med, 377, pp.829~838 (2017)
- Camidge DR, "Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC : final results of phase 3 ALTA-1L trial", J Thorac Oncol, 16, pp.2091~2108 (2021)
- Mok T, "Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study", Ann Oncol, 31, pp.1056~1064 (2020)
- Shaw AT, "First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer", N Engl J Med, 383, pp.2018~2029 (2020)
- Skoulidis F, "Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy", Nat Rev Cancer, 19, pp.495~509 (2019)
- Lee JK, "Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation", Lung Cancer, 77, pp.460~463 (2012)
- Rolfo C, "Liquid biopsy for advanced NSCLC : a consensus statement from the International Association for the Study of Lung Cancer", J Thorac Oncol, 16, pp.1647~1662 (2021)
- Kang MJ, "Cancer statistics in Korea : incidence, mortality, survival, and prevalence in 2020", Cancer Res Treat, 55, pp.385~399 (2023)